MagnetisMM-20

This clinical trial is organized into three different parts. This trial is open-label, which means that the participants and study team will know which part they are enrolled in, and which drugs/doses they will be receiving. Participants will be enrolled in only one part of the study, and will not be allowed to participate in other parts (rollover). 

In Part 1, researchers will evaluate the safety and best dose of elranatamab when combined with carfilzomib and dexamethasone. In Arm A of Part 2, researchers will evaluate the safety and best dose of PF-07901801 (maplirpacept) both by itself, and in combination with elranatamab. In Arm B of Part 2, researchers will give participants the doses of elranatamab and PF-07901801 (maplirpacept) determined to be safest and most effective by the previous groups.

The total length of this study can be 2 years or longer. You will continue to receive the study medicines until your multiple myeloma has progressed, you experience side effects that are hard to manage, or you choose to stop receiving the study medicines. You are free to stop being in the study at any time and for any reason; this will not affect your future medical care in any way.